Retraction notice to "Use of ivermectin in the treatment of Covid-19: A pilot trial" [Toxicol. Rep. 8 (2021) 505-510]

Affiliations

¹ Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
² Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461 Bronx, NY, United States.
³ University Hospital of the Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
⁴ Department of Genetics and Evolution, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.

Henrique Pott-Junior et al. Toxicol Rep. 2022.

. 2022 May 2:9:1023.

doi: 10.1016/j.toxrep.2022.04.009. eCollection 2022.

¹ Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
² Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461 Bronx, NY, United States.
³ University Hospital of the Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
⁴ Department of Genetics and Evolution, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.

Abstract

[This retracts the article DOI: 10.1016/j.toxrep.2021.03.003.].

Use of ivermectin in the treatment of Covid-19: A pilot trial.
Pott-Junior H, Paoliello MMB, Miguel AQC, da Cunha AF, de Melo Freire CC, Neves FF, da Silva de Avó LR, Roscani MG, Dos Santos SS, Chachá SGF. Pott-Junior H, et al. Toxicol Rep. 2021;8:505-510. doi: 10.1016/j.toxrep.2021.03.003. Epub 2021 Mar 9. Toxicol Rep. 2021. Retraction in: Toxicol Rep. 2022 May 02;9:1023. doi: 10.1016/j.toxrep.2022.04.009. PMID: 33723507 Free PMC article. Retracted.